LYTIR

Company · ALMS

Alumis Inc.

Name as listed on its exchange; filed with the SEC as ALUMIS INC.

Nasdaq's symbol directory lists ALMS on Nasdaq as “Alumis Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($10.7M); insiders sold on 14 occasions ($1.6M); 5 filings by holders of 5% or more.

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $10.7M in total; Insider sales: $1.6M in total.Jul: Insider sales $140KAug: Insider sales $394KSep: Insider purchases $10.7MSep: Insider sales $1.0MNov: Insider sales $24KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $10.7MInsider sales below: $1.6M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Srinivas Akkaraju sold on 1 day bought on 2 days latest Sep 8, 2026 sold $1.0M · bought $10.7M
  2. Pangali Sanam, Chief Legal Officer sold on 3 days latest Nov 2, 2026 sold $178K
  3. Schroer John R., Chief Financial Officer sold on 2 days latest Nov 2, 2026 sold $92K
  4. Hardiman Roy C., Chief Business & Strategy Ofcr sold on 2 days latest Nov 2, 2026 sold $75K
  5. Goldstein David M, Chief Scientific Officer sold on 2 days latest Nov 2, 2026 sold $73K
  6. Bradley Mark Christopher, Chief Development Officer sold on 2 days latest Nov 2, 2026 sold $72K
  7. Drappa Jorn, Chief Medical Officer sold on 2 days latest Nov 2, 2026 sold $68K
Every trade (16)
  1. SELLSchroer John R., Chief Financial Officer sold Nov 2, 2026 794 shares filing $5K
  2. SELLHardiman Roy C., Chief Business & Strategy Ofcr sold Nov 2, 2026 652 shares filing $4K
  3. SELLGoldstein David M, Chief Scientific Officer sold Nov 2, 2026 629 shares filing $4K
  4. SELLBradley Mark Christopher, Chief Development Officer sold Nov 2, 2026 623 shares filing $4K
  5. SELLDrappa Jorn, Chief Medical Officer sold Nov 2, 2026 593 shares filing $4K
  6. SELLPangali Sanam, Chief Legal Officer sold Nov 2, 2026 332 shares filing $2K
  7. BUYSrinivas Akkaraju bought Sep 8, 2026 546,581 shares 2 legs combined filing $5.8M
  8. SELLSrinivas Akkaraju sold Sep 8, 2026 96,131 shares 2 legs combined filing $1.0M
  9. BUYSrinivas Akkaraju bought Sep 4, 2026 440,140 shares 2 legs combined filing $4.9M
  10. SELLSchroer John R., Chief Financial Officer sold Aug 3, 2026 3,282 shares filing $87K
  11. SELLHardiman Roy C., Chief Business & Strategy Ofcr sold Aug 3, 2026 2,692 shares filing $71K
  12. SELLGoldstein David M, Chief Scientific Officer sold Aug 3, 2026 2,596 shares filing $68K
  13. SELLBradley Mark Christopher, Chief Development Officer sold Aug 3, 2026 2,572 shares filing $68K
  14. SELLDrappa Jorn, Chief Medical Officer sold Aug 3, 2026 2,447 shares filing $65K
  15. SELLPangali Sanam, Chief Legal Officer sold Aug 3, 2026 1,364 shares filing $36K
  16. SELLPangali Sanam, Chief Legal Officer sold Jul 6, 2026 5,000 shares filing $140K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 17,400 shares filing 0%
  2. Foresite Capital Fund VI LP filed Aug 17, 2026 Schedule 13D may seek influence 2,203,800 shares filing 3.5%
  3. FMR LLC filed Aug 6, 2026 Schedule 13G passive 6,769,170 shares filing 5.5%
  4. BlackRock, Inc. filed Jul 27, 2026 Schedule 13G passive 7,069,502 shares filing 5.7%
  5. AyurMaya Capital Management Company, LP filed Jul 2, 2026 Schedule 13D/A may seek influence 15,139,707 shares filing 12.3%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.